Floatz logo

esk981

Stage IV Prostate Adenocarcinoma AJCC v7

Barbara Ann Karmanos Cancer InstitutePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

97 Active assets in the Stage IV Prostate Adenocarcinoma AJCC v7 cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 2BB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

esk981 is also rated in:

hypogonadismDormant
B
Indicative ·
57 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →
PSA ProgressionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →